RxDoctor Payments Data

Joni Steele

Family · Terre Haute, INNPI 1093938177

Payments from drug & device makers

$1,993in general payments, 2019–2025

Across 79 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$386
  • Novartis$306
  • Boehringer Ingelheim$226
  • E.r. Squibb & Sons, L.L.C.$166
  • Novo Nordisk$150
  • Endologix LLC$122
  • plus $637 from 14 others

What the payments were for

  • Food & beverage$1,97399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,993 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$61,989
Medicare patients
557
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$94,534
EntrestoSacubitril/Valsartan53$42,397
XareltoRivaroxaban42$27,934
JardianceEmpagliflozin13$13,893
MultaqDronedarone Hcl11$8,546
Dabigatran EtexilateDabigatran Etexilate Mesylate13$4,484
Ranolazine ErRanolazine28$2,301
Midodrine Hcl16$1,717
Metoprolol Succinate149$1,433
Isosorbide Mononitrate ErIsosorbide Mononitrate188$1,211
Diltiazem 24hr Er (Cd)Diltiazem Hcl50$1,011
Metoprolol Tartrate234$996
Ezetimibe46$880
Nitroglycerin52$701
Atorvastatin Calcium130$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$94,534131 claims
NovartisEntresto$306$42,39753 claims
Johnson & JohnsonXarelto$32$27,93442 claims
Boehringer IngelheimJardiance$226$13,89313 claims
Sanofi-aventis U.S. LLCMultaq$20$8,54611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →